Adaptive Biotechnologies Corp
ADPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.61B
Close$
$3.64
83.9% downside
Current Fair Value
83.9% downsideOvervalued by 83.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.61 Billion |
|---|---|
| Enterprise Value | $3.79 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 2.07 |
| Outstanding Shares | 157,700,126 |
Return
| Return on Equity | -29.52% |
|---|---|
| Return on Assets | -12.62% |
| Return on Invested Capital | -8.71% |
Valuation & Multiples
| P/E Ratio | -55.4 |
|---|---|
| PEG | -100.11 |
| Price to Sales | 22.57 |
| Price to Book Ratio | 22.57 |
| Enterprise Value to Revenue | 12.31 |
| Enterprise Value to EBIT | -103.98 |
| Enterprise Value to Net Income | -60 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 1.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$65.44 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$65.44 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 15.11% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.43%▼ 95.74% |
|---|---|
| Total Invested | $114.24M▼ 94.58% |
| Investors Holding | 73▼ 226.00% |
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...